secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2024-10-21T23:59:59+00:00
Accession:  0001213900-24-089108
Event type: regulatory
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CERo submits complete response letter to FDA clinical hold for CERO-1236; clinic entry now expected early 2025
--------------------------------------------------------------------------------

- Submitted complete response to FDA clinical hold on CERO-1236; 30-day review cycle expected.
- Adjusted clinical trial entry from 2024 to early 2025 based on FDA timeline.
- Cash balance of $3.2M as of Sept 30, 2024, sufficient for near-term strategy execution.
- Al Kucharchuk appointed CFO; Kristen Pierce promoted to Chief Development Officer.
- Board of Directors changes made to enhance business plan execution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390024089108/0001213900-24-089108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390024089108/ea021808801-8k_cero.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-089108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer